Related Experiment Videos

Multidrug resistance

M I Tiirikainen1, T Krusius

  • 1Finnish Red Cross, Blood Transfusion Service, Helsinki.

Annals of Medicine
|January 1, 1991
PubMed

Insights

Malignant cells develop multidrug resistance (MDR) via P-glycoprotein, a pump that reduces drug accumulation. Understanding and reversing this P-glycoprotein function is key to improving chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Malignant cell resistance to chemotherapy limits treatment success.
  • Multidrug resistance (MDR) is often mediated by P-glycoprotein (P-gp) overexpression.
  • P-gp acts as an efflux pump, reducing intracellular cytotoxic drug concentrations.

Purpose of the Study:

  • To explore the role of P-glycoprotein in multidrug resistance.
  • To investigate the correlation between P-glycoprotein expression and clinical drug resistance.
  • To identify strategies for preventing P-gp function and reversing drug resistance.

Main Methods:

  • Analysis of P-glycoprotein expression in malignant cells.
  • Correlation studies between P-gp levels and patient response to chemotherapy.
  • Investigation of potential mechanisms to inhibit P-gp activity.

Main Results:

  • P-glycoprotein overexpression is linked to simultaneous resistance to multiple unrelated drugs.
  • P-gp is present in normal tissues, potentially contributing to intrinsic resistance.
  • Acquired multidrug resistance during chemotherapy is frequently associated with P-gp.

Conclusions:

  • P-glycoprotein is a significant factor in both intrinsic and acquired multidrug resistance.
  • Targeting P-glycoprotein offers a potential strategy to overcome chemotherapy resistance.
  • Further research is needed to elucidate P-gp's physiological role and therapeutic inhibition.

Related Concept Videos